Published in Health and Medicine Week, July 11th, 2005
"Previous studies in Caucasian patients showed treatment of chronic hepatitis C with pegylated interferon/ ribavirin was well tolerated, and produced a higher response rate especially in genotype 1 infections. However, it is unknown whether this conclusion can be extrapolated to patients with Chinese ethnic origin," scientists writing in the Journal of Viral Hepatitis report.
"A total of 153 patients with biopsy-proven chronic hepatitis C were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.